Industry Report – Integrated CPU And Bioanalytical Services Deliver Reduced Cycle Time And Cost Savings For Early Phase Trial Sponsors

In early phase development, where time is of the essence, it is critical that processes be calibrated to minimize downtime. Worldwide Clinical Trials’ early phase services (EPS) include a clinical pharmacology unit (CPU) and a bioanalytical (BioA) lab in San Antonio and Austin, Texas, respectively, strategically co-located to optimize efficiencies and reduce timeline lags.

Our internal research on early phase development reveals that the unique geographic placement of CPU and BioA facilities enable Worldwide’s EPS teams to trim cycle time and reduce study costs for early phase trial sponsors through reduced shipping delays and integrated cross-facility communications.

These efficiencies are critical to the support of trial sponsors that are managing multiple-cohort trials and those that are re-examining old compounds for new applications.